Sustainable Funding for Regulatory Science: FDA, Industry Hope Fourth Time is the Charm
This article was originally published in RPM Report
FDA is trying one more time to secure significant resources to fund regulatory science. FDA's leadership is making good progress with key figures in the Administration and on the Hill-but the money still isn't there.
You may also be interested in...
Former CMS Administrator (and ex FDA Commissioner) Mark McClellan argues that the Aduhelm experience shows why the Medicare agency needs a bump in appropriations.
Everyone knows R&D productivity has dipped to levels that threaten the private drug development model, and almost everyone says regulatory hurdles are part of the problem. That isn’t how FDA sees it. One thing is clear: blaming FDA won’t help anyone, so it may be time to pay more attention to FDA’s ideas for solutions rather than continue to point fingers.
Commissioner Hamburg and Rep. Rosa DeLauro draw on siimilar themes--and similar words--in making the case for regulatory science.